Lung cancer continues to be the leading cause of cancer-related deaths for Americans. As most patients present with nonsurgically curable disease, major efforts have been made in the treatment of advanced non-small-cell lung cancer (NSCLC) with chemotherapy. Several new agents and new combinations of chemotherapy are available.
Methods
The author reviews randomized clinical trials investigating chemotherapy for advanced NSCLC in chemotherapy-naive patients, in patients who present with relapsed or progressive disease, and in elderly patients. Therapies that incorporate new biological agents to target specific aberrations in lung cancer are discussed.
Results
Several clinical trials demonstrate improvement in overall survival as well as quality of life with chemotherapy treatment of advanced NSCLC. Better options are available for patients who have relapsed after first-line chemotherapy, and treatment of elderly patients with chemotherapy has demonstrated benefit in survival and quality of life. New agents that target molecular pathways are being tested in patients with early-stage disease.
Conclusions
Despite progress with newer agents for the treatment of advanced NSCLC, only 14% of patients with the disease are alive at 5 years after initial diagnosis. New therapies are needed.
References
1.
GreenleeR.T., MurrayT., BoldenS.. Cancer statistics, 2000.CA Cancer J Clin.2000; 50: 7–33.
2.
IhdeD.C.Chemotherapy of lung cancer.N Engl J Med.1992; 327: 1434–1441.
3.
Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.BMJ.1995; 311: 899–909.
4.
BonomiP.D., FinkelsteinD.M., RuckdeschelJ.C.. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.J Clin Oncol.1989; 7: 1602–1613.
5.
KlasterskyJ., SculierJ.P., LacroixH.. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer. Protocol 07861.J Clin Oncol.1990; 8: 1556–1562.
6.
SandlerA.B., NemunaitisJ., DenhamC.. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol.2000; 18: 122–130.
7.
CardenalF., Lopez-CabrerizoM.P., AntonA.. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol.1999; 17: 12–18.
8.
CrinoL., ScagliottiG.V., RicciS.. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project.J Clin Oncol.1999; 17: 3522–3530.
9.
CrawfordJ., O'RourkeM., SchillerJ.H.. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.J Clin Oncol.1996; 14: 2774–2784.
10.
Le ChevalierT., BrisgandD., DouillardJ.Y.. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.J Clin Oncol.1994; 12: 360–367.
11.
WozniakA.J., CrowleyJ.J., BalcerzakS.P.. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.J Clin Oncol.1998; 16: 2459–2465.
12.
RansonM., DavidsonN., NicolsonM.. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.J Natl Cancer Inst.2000; 92: 1074–1080.
13.
BonomiP., KimK., FaircloughD.. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.J Clin Oncol.2000; 18: 623–631.
14.
GatzemeierU., von PawelJ., GottfriedM.. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.J Clin Oncol.2000; 18: 3390–3399.
15.
BelaniC.P., NataleR.B., LeeJ.S.. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC).Proc Annu Meet Am Soc Clin Oncol.1998; 17. Abstract 1751.
16.
KellyK., CrowleyJ., BunnP.A.. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial.Proc Annu Meet Am Soc Clin Oncol.1999; 18. Abstract 1777.
17.
SchillerJ., HarringtonD., SandlerA.. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC).Proc Annu Meet Am Soc Clin Oncol.2000; 19. Abstract 2.
FossellaF.V., DeVoreR., KerrR.N.. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol.2000; 18: 2354–2362.
21.
ShepherdF.A., DanceyJ., RamlauR.. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.J Clin Oncol.2000; 18: 2095–2103.
22.
CrinoL., MosconiA.M., ScagliottiG.. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial.J Clin Oncol.1999; 17: 2081–2085.
23.
RosvoldE., LangerC.J., SchilderR.. Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P).Proc Annu Meet Am Soc Clin Oncol.1998; 17. Abstract 1797.
24.
PronzatoP., LanducciM., VairaF.. Failure of vinorelbine to produce responses in pretreated non-small-cell lung cancer patients.Anticancer Res.1994; 14: 1413–1416.
25.
RinaldiM., Della GiuliaM., VenturoI.. Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer.Proc Annu Meet Am Soc Clin Oncol.1994; 13: 360a. Abstract 1212.
26.
SandoroA., Maiorinol SandoroM.. Second-line treatment with vinorelbine in the weekly monotherapy chemotherapy for the treatment of advanced non-small cell lung cancer.Lung Cancer.1994; 11(suppl 1): 130. Abstract 497.
27.
AlbainK.S., CrowleyJ.J., LeBlancM.. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.J Clin Oncol.1991; 9: 1618–1626.
28.
Giovanazzi-BannonS., RademakerA., LaiG.. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study.J Clin Oncol.1994; 12: 2447–2452.
29.
WalshS.J., BeggC.B., CarboneP.P.. Cancer chemotherapy in the elderly.Semin Oncol.1989; 16: 66–75.
30.
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group.J Natl Cancer Inst.1999; 91: 66–72.
31.
FrasciG., LorussoV., PanzaN.. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.J Clin Oncol.2000; 18: 2529–2536.
32.
RyanP.D., ChabnerB.A.. On receptor inhibitors and chemotherapy.Clin Cancer Res.2000; 6: 4607–4609.
33.
CarboneD.P.. The biology of lung cancer.Semin Oncol.1997; 24: 388–401.
34.
CarboneD.P.. Molecular modalities in the treatment of lung cancer.Oncology (Huntingt).1999; 13: 142–147.
35.
FerryD., HammondL., RansonM.. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study.Proc Annu Meet Am Soc Clin Oncol.2000; 19. Abstract 5E.
36.
KernJ.A., SchwartzD.A., NordbergJ.E.. p185neu expression in human lung adenocarcinomas predicts shortened survival.Cancer Res.1990; 50: 5184–5187.
37.
KernJ.A., TorneyL., WeinerD.. Inhibition of human lung cancer cell line growth by an anti-p 185HER2 antibody.Am J Respir Cell Mol Biol.1993; 9: 448–454.
38.
KernJ.A., SlebosR.J., TopB.. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.J Clin Invest.1994; 93: 516–520.
39.
BunnP., SorianoA., HelfrichB.. HER2/neu expression and effects of Herceptin alone and in combination with cytotoxic agents in lung cancer.Proc Annu Meet Am Assoc Cancer Res.2000. Abstract 4571.
40.
ZhangY.A., NemunaitisJ., TongA.W.. Generation of a ribozymeadenoviral vector against K-ras mutant human lung cancer cells.Mol Biotechnol.2000; 15: 39–49.
41.
SebtiS.M., HamiltonA.D.. Farnesyltransferase and geranylger-anyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.Expert Opin Investig Drugs.2000; 9: 2767–2782.
42.
EskensF.A., AwadaA., CutlerD.L.. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.J Clin Oncol.2001; 19: 1167–1175.
43.
MoasserM.M., Sepp-LorenzinoL., KohlN.E.. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.Proc Natl Acad Sci U S A.1998; 95: 1369–1374.
44.
NemunaitisJ., HolmlundJ.T., KraynakM.. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.J Clin Oncol.1999; 17: 3586–3595.
45.
CunninghamC.C., HolmlundJ.T., SchillerJ.H.. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.Clin Cancer Res.2000; 6: 1626–1631.
46.
DeVoreR.F., FehrenbacherL., HerbstR.S.. A randomized phase II trial comparing rhuMAB VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC.Proc Annu Meet Am Soc Clin Oncol.2000; 19. Abstract 1896.
47.
MerchantJ.J., HammesL.C., LarsonM.L.. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer.Proc Annu Meet Am Soc Clin Oncol.2000; 19. Abstract 2130.
WeillD., MackM., RothJ.. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.Chest.2000; 118: 966–970.
50.
SwisherS.G., RothJ.A., NemunaitisJ.. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.J Natl Cancer Inst.1999; 91: 763–771.
51.
NemunaitisJ., SwisherS.G., TimmonsT.. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell cancer.J Clin Oncol.2000; 18: 609–622.
52.
KubbaS., AdakS., SchillerJ.. Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage.Proc Annu Meet Am Soc Clin Oncol.2000; 19. Abstract 1904.
53.
NemunaitisJ.. Oncolytic viruses.Invest New Drugs.1999; 17: 375–386.
54.
NemunaitisJ., GanlyI., KhuriF.. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.Cancer Res.2000; 60: 6359–6366.
55.
LeeJ.H., LeeC.T., YooC.G.. The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line.Anticancer Res.1998; 18: 3257–3261.
56.
LeeC.T., WuS., GabrilovichD.. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.Cancer Res.1996; 56: 3038–3041.
